Clinical Trials Directory

Trials / Terminated

TerminatedNCT03206879

Fecal ESBL Resurgence During Antibiotic Treatment

Status
Terminated
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
University Hospital, Akershus · Academic / Other
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

Norwegian hospitals are struggling to control spread of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) in health care settings. Strict screening and isolation criteria are enforced in hospital, and patients previously infected by ESBL-E are regarded as possible ESBL-E carriers indefinitely. This observational multi-centre cross-sectional study aims to estimate the duration of fecal ESBL-E carriage and to assess the risk of ESBL-E resurgence during hospital stay for patients previously infected by ESBL-E. Through better knowledge of these risk factors, infection control procedures may be better tailored to rhe individual patient.

Conditions

Timeline

Start date
2016-11-01
Primary completion
2018-08-01
Completion
2018-12-01
First posted
2017-07-02
Last updated
2024-02-06

Source: ClinicalTrials.gov record NCT03206879. Inclusion in this directory is not an endorsement.

Fecal ESBL Resurgence During Antibiotic Treatment (NCT03206879) · Clinical Trials Directory